4D pharma plc (DDDD.L)
- Business Wire
4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit
LEEDS, England, October 12, 2021--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D management will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit being held on October 19, 2021.
- Business Wire
4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021
LEEDS, England, September 15, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces new biomarker analyses from two ongoing clinical trials of its lead immuno-oncology single strain Live Biotherapeutic, MRx0518, in both neoadjuvant and refractory solid tumor settings, at the European Society for Medical Oncology (ESMO) Congress, September 16-21, 202
- Business Wire
4D pharma to Participate in Upcoming Virtual Investor Conferences in September
LEEDS, England, September 09, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that 4D pharma management will present at the following virtual investor conferences:
